133 related articles for article (PubMed ID: 38677746)
21. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
22. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
23. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
24. Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
Kim HD; Park YG; Kim S; Kim KP; Park SR; Ryu MH; Ryoo BY; Yoo C
Hepatol Int; 2024 Jun; 18(3):973-983. PubMed ID: 38214792
[TBL] [Abstract][Full Text] [Related]
25. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
26. Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Matsuzaki T; Hashimoto S; Ohba K; Kugiyama Y; Yatsuhashi H; Shibata H; Motoyoshi Y; Shigeno M; Iwatsu S; Kato Y; Kinoshita N; Nakao K
Anticancer Res; 2021 Apr; 41(4):2025-2032. PubMed ID: 33813409
[TBL] [Abstract][Full Text] [Related]
27. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
31. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
32. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
[TBL] [Abstract][Full Text] [Related]
34. Sequential systemic treatment in patients with hepatocellular carcinoma.
Kirstein MM; Scheiner B; Marwede T; Wolf C; Voigtländer T; Semmler G; Wacker F; Manns MP; Hinrichs JB; Pinter M; Vogel A
Aliment Pharmacol Ther; 2020 Jul; 52(1):205-212. PubMed ID: 32432799
[TBL] [Abstract][Full Text] [Related]
35. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
[TBL] [Abstract][Full Text] [Related]
36. Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.
Muto H; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
Medicine (Baltimore); 2021 Aug; 100(31):e26820. PubMed ID: 34397843
[TBL] [Abstract][Full Text] [Related]
37. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
[TBL] [Abstract][Full Text] [Related]
38. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
39. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
40. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]